Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2013 / Article
Special Issue

Oxidative Stress and Aging Diseases

View this Special Issue

Review Article | Open Access

Volume 2013 |Article ID 971024 | https://doi.org/10.1155/2013/971024

Mario Arciello, Manuele Gori, Clara Balsano, "Mitochondrial Dysfunctions and Altered Metals Homeostasis: New Weapons to Counteract HCV-Related Oxidative Stress", Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 971024, 10 pages, 2013. https://doi.org/10.1155/2013/971024

Mitochondrial Dysfunctions and Altered Metals Homeostasis: New Weapons to Counteract HCV-Related Oxidative Stress

Academic Editor: Peter Shaw
Received10 Jun 2013
Revised18 Oct 2013
Accepted28 Oct 2013
Published24 Nov 2013


The hepatitis C virus (HCV) infection produces several pathological effects in host organism through a wide number of molecular/metabolic pathways. Today it is worldwide accepted that oxidative stress actively participates in HCV pathology, even if the antioxidant therapies adopted until now were scarcely effective. HCV causes oxidative stress by a variety of processes, such as activation of prooxidant enzymes, weakening of antioxidant defenses, organelle damage, and metals unbalance. A focal point, in HCV-related oxidative stress onset, is the mitochondrial failure. These organelles, known to be the “power plants” of cells, have a central role in energy production, metabolism, and metals homeostasis, mainly copper and iron. Furthermore, mitochondria are direct viral targets, because many HCV proteins associate with them. They are the main intracellular free radicals producers and targets. Mitochondrial dysfunctions play a key role in the metal imbalance. This event, today overlooked, is involved in oxidative stress exacerbation and may play a role in HCV life cycle. In this review, we summarize the role of mitochondria and metals in HCV-related oxidative stress, highlighting the need to consider their deregulation in the HCV-related liver damage and in the antiviral management of patients.

1. Introduction

Hepatitis C virus (HCV) is a human pathogen affecting about 4 million new subjects every year [1]. Approximately 3% of the world’s population is estimated to be chronically infected by HCV [2]. Differently from the other hepatitis viruses (A, B, and E), more than 80% of HCV patients become chronic [3].

HCV is a member of the genus Hepacivirus of Flaviviridae family. It is a single-stranded RNA virus with positive polarity. The genome of HCV encodes a polyprotein of about 3000 amino acids that is expressed from a single long open reading frame (ORF). This polyprotein is cleaved into ten different products: the core protein (Core) and the envelope glycoproteins 1 and 2 (E1 and E2, resp.), which are constituents of the HCV particles, p7 and nonstructural protein 2 (NS2), primarily involved in HCV assembly, NS3, NS4A, NS4B, NS5A, and NS5B nonstructural proteins with important roles in the polyprotein processing and HCV replication [4]. HCV infection frequently leads to severe liver diseases, including liver cirrhosis and HCC [5]. Chronic HCV infected patients are commonly characterized by metabolic derangements, such as steatosis, insulin resistance (IR), and altered homeostasis of trace metals [68]. Many works suggest that oxidative stress (OS) plays a pivotal role in the occurrence of all these pathological features. OS is the condition occurring when the cellular or systemic redox balance is altered, as a consequence of unusual exposure to prooxidant molecules, like reactive oxygen species (ROS) or reactive nitrogen species (RNS) [9], which in turn can be either associated with an inadequate antioxidant response or not. The overproduction of ROS and RNS can be caused either by endogenous or exogenous sources [9]. OS produces oxidative damage to proteins, lipids, and nucleic acids, thus altering their physiological functions.

Mitochondria are the main source of ROS production through the electron transport chain (ETC) complexes and the mitochondrial dehydrogenases [10] and, at the same time, they are the main targets of reactive molecules. Mitochondria are well-known targets of HCV protein actions; however, also extramitochondrial sources of ROS are involved in HCV-related OS onset: ER, peroxisomes and other cell compartments [11, 12], xanthine oxidase or NADPH oxidases [13], cytochromes P450, and resident immune cell populations in the liver (e.g., Kupffer cells). To avoid the deleterious effects of ROS, biological systems have developed several mechanisms of detoxification that use a wide number of small molecules, peptides, and enzymes, like glutathione (GSH) or superoxide dismutases (SODs), respectively.

However, it should not be forgotten that ROS are also potent second messengers in a plethora of cellular functions; they are involved in modulating key physiopathological processes [14, 15], such as those mediated by the signal transducer and activator of transcription (STAT) and nuclear factor kappa-light-chain enhancer of activated B cells (NFκB) [16].

This review will summarize some relevant mechanisms through which HCV may promote OS onset, focusing the attention on virus-related mitochondrial OS, trace elements derangement, and novel therapeutic opportunities to counteract these viral actions.

2. Oxidative Stress during HCV Infection

The OS occurrence, as a consequence of HCV infection, is well established [17]. Several reports put in evidence a deep redox imbalance in infected patients, focusing on its potential correlation with the course of the liver disease.

Increased markers of oxidative-damaged DNA (8-hydroxyguanosine, 8-OHdG) and lipid peroxidation products (8-isoprostane) were detected in serum, peripheral blood mononuclear cells (PBMC), and liver specimens of infected patients [5, 18, 19].

Accordingly, we recently demonstrated that HCV patients are characterized by increased plasma levels of 7-ketocholesterol (7K) and 7-β-hydroxycholesterol (7βOH) [20], two of the well-known peroxidation products of cholesterol, called oxysterols. Oxysterols are extremely interesting, not only because they can modulate the mitogen-activated protein kinases (MAPKs), thus affecting cell growth and promoting cell transformation [21], but also because they were detected in oxidized-low density lipoprotein (oxLDL) [22]. Oxysterols are the specific ligands of liver X receptors (LXRs), nuclear receptors deeply involved in several pathophysiological processes, for example, lipid metabolism and inflammation [23]; through oxysterols HCV might profoundly modulate host metabolism. Accordingly, steatosis is a common feature in HCV-infected hepatocytes [24] and it is characterized by high oxidation rates with a consequent increase of electron delivery to the ETC that might cause ROS overproduction. Infected patients show a correlation between OS markers and inflammation, grade of fibrosis, and hepatic iron storage [25, 26]. However, the increased levels of oxysterols give rise to the question whether the OS is directly due to HCV-host cell interactions or if host immune response and iron overload are main reasons for OS onset [2729]. Surely, a synergistic mechanism exists.

Moreover, HCV patients are deeply characterized by a reduction of their antioxidant defense. Glutathione (GSH), a key player of the first line of antioxidant defense, produced by all cells and especially concentrated in liver [30], is commonly decreased in chronic HCV subjects [3133]. Accordingly, the ratio between oxidized (GSSG) and reduced (GSH) forms, a well-accepted parameter representative of the oxidative status, is increased [32]. As well as GSH, glutathione reductase, glutathione peroxidase, and Cu/Zn containing SOD are often found decreased in PBMC of infected patients too [34].

All reported data demonstrate that OS occurrence is due to HCV, but some discrepancies exist about the entity of the induction of liver damage linked to this pathological mechanism. To note, OS markers are found in HCV patients with mild, moderate, or no liver disease [35]. However, proteomic analysis revealed an upregulation of antioxidant enzymes at early (F1 to F3) but not at late stages of fibrosis [36].

On the contrary, some works described an enhanced expression of thioredoxin (Trx) [37] or heme oxygenase (HO-1) [38]. The latter enzyme, in particular, is a known target gene of the nuclear factor erythroid2-like 2 (Nrf2) protein. This data seems in contrast with what we have previously described, but, in our opinion, the activation of Nrf2 could be functional to HCV virus. In fact, Nrf2 is a transcription factor which recognizes a common conservative sequence, called antioxidant response element (ARE), in the promoter regions of many antioxidant enzymes [39, 40], and is crucial to preserve the mitochondrial activities and to enhance cell survival of infected cells [41]. Thus is essential for viral life cycle.

3. Mitochondria: In the Center of the Viewfinder of HCV

As mentioned above, the main parts of ROS produced in the cells are generated by mitochondria. These organelles are the “cellular power plants,” because they are mainly responsible for cell supply of adenosine triphosphate (ATP). By sensing the energy status they may decide the cell fate [42]. The relevance of mitochondria to metabolism, energy production, and cell fate was brought to light by several reports in a plethora of human diseases, from neurodegeneration to metabolic disorders [43].

Several lines of evidence describe, without any doubt, mitochondria as a main target of the HCV virus. It is well known that HCV produces ultrastructural alteration of these organelles and causes oxidative damage and a reduction in mitochondrial DNA copy number, in both hepatocytes and lymphocytes of infected patients [44, 45].

Mitochondria possess a complex architecture; they comprise an outer membrane (OMM) that encloses the entire organelle and has a structure similar to that of plasma membrane. The OMM contains proteins and complexes that allow diffusion of small proteins or factors characterized by a specific signaling sequence at their N-terminus. The OMM can associate with the ER through a structure called mitochondria-associated ER membrane (MAM) [46]. MAMs are zones of junctions where the inner mitochondrial membrane (IMM) meets the OMM and allows exchanges of Ca2+ and lipid between ER and mitochondria [46]. Thus, MAMs are key elements in the maintenance of mitochondrial homeostasis of lipids and Ca2+ [46] and are crucial to modulating the opening of the mitochondrial permeability transition pore (mPTP). The latter is a critical event in the decision of cell fate [47]. Furthermore, MAMs have a key role in the cellular pathways leading to very-low-density lipoprotein (VLDL) assembly and secretion [48]. These cellular activities are also essential for the formation and maturation of HCV particles [49].

Several HCV proteins have been shown to directly associate with mitochondria [5052] (Figure 1). In particular, Core is able to associate with OMM through a specific sequence at its C-terminal region [53, 54]. It was detected in MAMs on the mitochondrial surface [53] and, by electronic microscopy; it was also localized in the IMM [52] (Figure 1). Biochemical studies revealed that the interaction of HCV with mitochondria, through the Core protein, plays a key role in organelles sensitization to Ca2+ influx, with the consequent opening of mPTP, release of cytochrome c [55], mitochondrial depolarization, and ETC failure. This cascade of events leads to an increased ROS generation (Figure 1).

Other viral proteins reinforce the Core action. Indeed, in experimental models, the proteins p7 and NS4A, the NS3/4A complex, and the proteins NS5A and NS5B were found to be localized to mitochondria and ER by subcellular-fractionation and confocal and electron microscopy [5559] (Figure 1). Furthermore, both NS5A and NS5B were also localized in the IMM and in the mitochondrial matrix [55, 58] (Figure 1).

These data clearly demonstrate the intimate connection of HCV to mitochondria.

The mitochondrial sensitization to Ca2+ along with the mPTP opening, caused by viral proteins, lead to building up a vicious circle characterized by the inhibition of the ETC, with the consequent increase in ROS production. This, in turn, induces mPTP opening [60, 61] and further worsening of mitochondrial failure (Figure 1).

One of the main mitochondrial targets of HCV is Complex I of ETC (also known as NADH:ubiquinone oxidoreductase) [62]. Complex I activity, being the first step of ETC, is crucial for the aerobic respiration. Mitochondria isolated from transgenic mice expressing Core, E1, and E2 glycoproteins are characterized by an increased ROS production from Complex I substrates and reduced Complex I activity [17, 50] (Figure 1). The Complex IV (cytochrome c oxidase) is the other mitochondrial protein complex affected by HCV (Figure 1). On the contrary, Complexes II and III are not altered during HCV infection [63]. It is interesting to note that the inhibition of viral replication, via IFN treatment, can fully restore the activities of both Complexes I and IV in hepatic cells [63].

Increased oxidation of the GSH and thioredoxin pools further provides a demonstration of the HCV-related mitochondrial redox imbalance [64, 65]. Core has also been shown to induce the expression of mitochondrial but not cytoplasmic SOD [65], suggesting that HCV generates ROS at mitochondrial level and, at the same time, strengthens the cellular antioxidant system against OS. The virus, to avoid excessive cytotoxic effects produced by a massive increase of ROS, might activate this behavior.

4. HCV and Metals Homeostasis Derangement

HCV infection may prompt OS onset by deregulation of homeostasis of trace metals, like zinc (Zn), iron (Fe), and copper (Cu) [8]. Zn, Fe, and Cu are essential trace elements that play important roles in various biological processes.

HCV patients show low plasma concentrations of Zn, whereas Cu and Fe concentrations were high [8, 66]. Notably, higher amounts of both Fe and Cu can interfere with Zn homeostasis, worsening the Zn deficiency [67].

Zn is largely present in the cells [68] and has several relevant biological functions: it is involved in insulin management [69] and in the maintenance of immune system [70]. Zinc is a redox inert metal; thus, it does not directly participate in cellular reactions of reduction and oxidation. The antioxidant potential of Zn is exerted through different mechanisms: (a) it is able to bind the sulfhydryl groups of proteins avoiding their oxidation by free radicals; (b) it participates in the antioxidant response through the modulation of metallothioneins, GSH, and Nrf2; (c) it may antagonize redox-active transition metals, such as Fe and Cu [68]. Zn has also a structural relevance to HCV because some of its proteins, that is, NS3 and NS5A, are zinc metalloproteins [71]. At hepatic level, Zn is known to promote antioxidant and anti-inflammatory effects that result in reduced hepatocyte injury, in chronic HCV infected patients [72, 73]; moreover, Zn is able to inhibit NFκB activation, thus counteracting the production of inflammatory cytokines [74]. HCV replication, instead, enhances the NFκB pathway activation triggered by tumor necrosis factor-alpha (TNFα) [75]; thus the low Zn plasma levels may prompt the onset of an inflammatory environment known to play a key role in virus-related liver disease progression. Accordingly, some studies suggest that zinc administration, through a drug called polaprezinc, may improve the outcome in HCV and HCV-related cirrhotic patients [76, 77]. The idea that low levels of Zn may be functional to HCV-related liver damage seems further supported by some studies that have suggested its potential in inhibiting HCV replication [78]; however, the mechanism is still not clear.

As well as in other pathologies, such as cancer or diabetes [70, 79, 80], in the HCV infection a Zn deficiency occurs parallel to a Cu increase [8], particularly in those patients affected by NAFLD as well [81], thus paving the way for a redox imbalance. The increase in Cu serum levels correlates with viral load [82]. Since Cu overload may lead to several deleterious effects, it is possible to speculate that the Zn therapy is beneficial for HCV patients because it also provokes a reduction in Cu levels, as already described in other pathologies like Wilson’s disease [83].

Cu, in fact, is a transition metal extremely harmful because, as well as Fe, it is characterized by an elevated redox potential; thus it may participate in redox reactions, like Fenton’s reaction, promoting ROS generation and consequently OS, as already reported in other tissues and pathologies [84]. To avoid its unhindered reactivity, biological systems developed an intricate network of proteins that prevents the existence of free copper. GSH, a key antioxidant, able to suppress Cu toxicity through its binding to this metal, maintains it in a reduced state and avoids its redox cycling [85]. GSH decrease, associated with Cu deregulation, may play a key role in the HCV-related OS onset. The role of Cu in HCV infection and the related OS is probably underestimated. Oxidative potential of Cu on low-density lipoprotein (LDL), in fact, is known for a long time [86]. This event not only has a clinical relevance in cardiovascular risk enhancement, but also may have a deep impact in HCV-related damage, even if some apparent contrasting data are reported. Several studies, in fact, describe the presence of a high level of oxLDLs in HCV infected patients [20, 87], according to the plasma Cu elevation, suggesting a possible role in disease pathogenesis; on the contrary, other papers suggest their potential role in inhibiting the HCV entry in the cells [88, 89]. Nevertheless, why should the virus produce something that could be able to inhibit its entry into cells? Currently, there is not an explanation. It could be a protective response of the organism; the oxidation of LDL, in fact, as a consequence of the inflammatory response activation, could be an attempt to counteract viral infection. Alternatively, it may only be a secondary phenomenon occurring only in a late phase as a result of the prooxidant environment generated by the HCV, also through the imbalance of transition metals homeostasis, such as copper. This latter hypothesis implies that LDL oxidation has actually a low impact in countering the infectivity of HCV, since it occurs only when the virus has already activated its pathological mechanisms. Although the oxidation of LDL is an event well established in HCV patients, the mechanisms underlying it are not well clarified. The topic is intriguing, and the role of Cu needs to be better explained, not only because Cu and oxLDL evaluations may have a deep diagnostic and prognostic impact, but also because a deep comprehension of their involvement in HCV-related disease could open the way to new antiviral approaches.

Altered Cu homeostasis is associated with a reduction of ceruloplasmin [9092]. This protein is important for both the trafficking of copper, binding 95% of circulating copper [70], and Fe, because, at hepatic level, it is the main ferroxidase enzyme, which is crucial for a proper Fe transport [93]. Thus, its deregulation may also represent a sign of systemic Fe perturbation.

As a matter of fact, patients with chronic HCV infection are commonly characterized by elevated levels of serum ferritin and hepatic iron [8]. Hepatic iron increase could be functional to viral cell cycle; in fact, a recent paper indicates that transferrin receptor 1 (Tfr1) may be important for the cell entry of viral particle [94]. The relevance of this metal is further highlighted by several studies and clinical trials that demonstrate how the hepatic iron levels influence hepatic injury and response to therapy in chronic HCV patients [9598]. Furthermore, patients with a virus-induced severe grade of hepatitis show higher levels of serum iron with respect to patients characterized by a lower grade of hepatitis. Note that serum iron is positively correlated with intense steatosis, fibrosis, and biochemical and histological parameters, indicating liver inflammation [99].

The mechanism underlying iron deregulation is still unclear; however, in such a context, hepcidin seems to be a key player. Hepcidin is a protein synthesized in the liver where iron, inflammation, and OS promote its expression [100]. This protein, through the modulation of ferroportin, is crucial for the maintenance of systemic iron homeostasis.

Through the use of a mouse model of HCV infection, it was suggested that the hepatic decrease of hepcidin causes an increased intracellular iron storage and, at the same time, OS. This, in turn, may promote the expression of ferroportin in the duodenum and in the macrophages, thus leading to increased iron serum levels [101]. This mechanism could explain the iron derangement in HCV patients. Furthermore, it was recently proposed that the HCV-related downregulation of hepcidin may also exert a deep impact on the virus life cycle, because it seems to possess an antiviral activity [102]. Therefore, through the hepcidin inhibition HCV reaches two goals to save its viral cycle and to promote derangement of iron homeostasis.

The latter event may be crucial in OS-mediated liver injury [103]. In fact, Fe is an extremely reactive transition metal, and an excessive presence may induce mitochondrial injury increasing the risk of HCC development [104]. Accordingly, a Fe reduction therapy has been shown to counteract hepatocyte injury in patients with HCV infection [97], confirming an important role of iron in HCV-related liver injury.

So, the OS induced by HCV promotes the onset of a dangerous loop involving, once again, mitochondrial damage; hence, the deranged homeostasis of metals may enhance ROS production and mitochondrial failure, which may participate in the alteration of metal homeostasis. Mitochondria, in fact, play a key role in the maintenance of Cu and Fe homeostasis [105, 106].

5. New Potential HCV Therapeutical Approaches

In the last decade, the gold standard in the HCV treatment was represented by the combination of pegylated interferon (IFN)-α and ribavirin. This therapy, administered for 24 or 48 weeks, produced viral suppression in approximately 40–50% of patients infected by HCV genotype 1 and in 80% of those infected by HCV genotypes 2 and 3 [107]. Today, the new therapeutic approach contemplates the use of a triple therapy, (IFN)-α and ribavirin plus telaprevir or boceprevir, two direct-acting antiviral (DAA) agents known to be NS3/NS4A protease inhibitors [107]. Unfortunately, although these new treatments reach a sustained viral response (SVR) in 63–75% HCV genotype 1 patients and a reduction in therapy length, persistent limitations to treatment still exist. In particular, many new side effects have been encountered which are in need of adequate management strategies as well as drug interactions, other than the persistence of virus resistance and interferon intolerance [108]. To overcome these problems today new therapeutic treatments are under investigation, such as DAA of second generation, targeting NS5B, or host targeting molecules, like cyclophilin inhibitors, and the use of IFN-free therapy, to reduce intolerance to treatment and to enlarge the potential patients cohorts [107].

The use of molecules counteracting oxidative stress at mitochondrial levels or treatments able to restore a proper metal homeostasis could be really helpful in HCV therapy. Accordingly, in fact, it was recently demonstrated that the use of a cell-permeant iron chelator and GSH ethyl ester decreased oxidative RNA damage, positive selection, and the nucleotide and amino acid substitution rates of HCV [109]; all these events are involved in the virus resistance to the antiviral therapy. Unfortunately, antioxidants and other strategies decreasing ROS/RNS in HCV patients achieved poor effects. In fact, when being used alone, antioxidants like N-acetylcysteine (NAC), vitamin E, or ascorbic acid ameliorate liver damage but did not affect HCV titer [107]; currently, only seldom, the outcome of antiviral therapy was improved when they were used in combination with IFN [107].

The above-mentioned scarce efficacy could be justified by the fact that the canonical antioxidants are not taken up into mitochondria, the major cellular source of damaging free radicals within cells [61]. To decrease specifically mitochondrial oxidative damage, mitochondria-targeted antioxidants have been developed like mitoquinone (MitoQ) [110, 111]. This novel class of compounds combines the antioxidant potential of ubiquinone with a lipophilic triphenylphosphonium cation, which facilitates the mitochondrial storage [111]. Some studies, both in vitro and in vivo, have shown that the selective mitochondrial accumulation of MitoQ enhances its antioxidant potential if compared to untargeted antioxidants [112]. This molecule, which accumulates in the liver after oral administration [110], was employed in phase II trials against HCV [113]. Despite its scarce impact on the viral load, it was able to decrease the liver damage. It is conceivable to imagine that the great reduction of OS and inflammation, due to its mitochondrial specificity, may be highly detrimental for the virus persistence.

Another class of molecules that gained great interest as antioxidant and mitochondrially targeted antiviral agents is the analogues of cyclosporine A (CsA), for example, the cyclophilin (Cyp) inhibitors [114]. They are nonimmunosuppressive molecules and have a great anti-HCV potential, as demonstrated by in vivo and in vitro studies [115117]. The prototype of this class of molecules is Alisporivir (also known as Debio-025 or DEB025) [118]. This drug, besides its ability to counteract viral replication, was demonstrated to prevent the HCV-related mitochondrial respiration dysfunctions, the collapse of mitochondrial membrane potential, the consequent ROS overproduction, and the mitochondrial calcium overload [119]. Cyp inhibitors are host oriented therapeutic, and for this reason, their use in the common clinical practice is difficult because of the risk of cell toxicity; even clinical and experimental data push towards this direction.

Another mechanism through which it is possible to counteract the HCV-related OS is the maintenance or the rescue of a correct metals homeostasis. In fact, the positive effects reached through a Zn supplementation on the HCV-related liver damage were described, although viral titer was not affected [120]. Other reports, indeed, describe that phlebotomy treatment, done to reduce the circulating iron content, produces a 2.95 odds ratio of response to IFN therapy [121]. To date, the potential effect of copper reduction in HCV treatment was not yet described, but we need to keep in mind an interesting issue. Recently, the ability of a wide range of natural polyphenols to counteract various steps of HCV life cycle, like cell entry, replication, or spreading was deeply reviewed [122]. Of particular interest among these molecules are quercetin, (−)-Epigallocatechin-3-gallate (EGCG), and Silymarin/Silibinin [122], because they are known to be powerful antioxidants. However, a property of these compounds, too often underestimated, is their ability to bind reactive metals like Fe and Cu [123, 124]. This behavior is extremely interesting, but to date its relevance in HCV treatment has not been yet investigated. Through the metal binding, in fact, polyphenols could exert their antiviral actions via different mechanisms, because not only they can control metals redox reactivity, counteracting the OS occurrence, but also through the modulation of intracellular metal content, they could hinder the activity of some viral proteins, for example, NS3 or NS5A. It could be imagined that polyphenols, reaching and penetrating the hepatocytes, once bound to Fe or Cu, can cause an intracellular rise of metal levels, which can, in turn, counteract the viral replication. Accordingly, it has been reported that increased intracellular levels of Fe and Cu can create a hostile environment for the life cycle of the virus [125, 126].

On these bases, the use of molecules with an antioxidant potential, targeting mitochondria, or being able to bind metals, could be really helpful to eradicate HCV infection, at least as treatments complementary to gold standard therapies. On the other hand, a deeper knowledge of the mechanisms of action of such compounds can reveal new interesting abilities that could lead to the formulation of new efficient therapies with less side effects and major tolerance.

6. Discussion

The hepatitis C virus promotes a prooxidant cellular status through several molecular mechanisms. While at cellular level mitochondria appear to be the most affected organelles, at systemic level the deregulation of trace metals homeostasis is associated with pathological mechanisms involving OS and inflammation, which in turn may be once more correlated with mitochondrial failure. Furthermore, if we consider the fact that HCV infection is associated with a decrease of antioxidant defenses, it leaps to the eyes that the increase of ROS is not efficiently counteracted. Thus, the virus establishes a vicious circle in which the molecules can suffer oxidative damage with the consequent alteration of their physiological functions.

To this regard, an antioxidant therapy could be useful to counteract, at least in part, the pathological consequences caused by HCV-related OS. Unfortunately, until now, antioxidant therapy had scarce effectiveness, either if used alone or combined with interferon (IFN) antiviral treatment [127]. In fact, as previously reported, the main goal reached by antioxidant supplementation is the reduction of OS and inflammatory state caused by HCV, which causes, in turn, a reduction of virus-related liver damage.

On the other hand, we need to keep in mind that HCV induces OS through numerous molecular pathways, for example, mitochondrial damage (Figure 1) and altered metal homeostasis; thus it is difficult to imagine an antioxidant approach with a such wide range of action. Furthermore, it should always be remembered that HCV produces several other effects besides the OS; thus, we think that the antioxidant effects may be helpful to counteract HCV-related damage, but it is likely that they are not so effective if used alone. Probably, the use of antioxidants able to selectively target mitochondria can more efficiently counteract the OS related mitochondrial dysfunctions, thus leading to more powerful healthy effects than those obtained through the use of canonical untargeted antioxidants.

Another potentially effective approach is the use of natural polyphenols to counteract the OS related to HCV infection. Several natural compounds have shown antiviral effects counteracting viral entry (e.g., Honokiol), replication (e.g., Quercetin), or spreading (e.g., Silymarin) [122]. Natural compounds are known to be powerful antioxidants, and some of them are also able to bind Cu and Fe, controlling, in this way, their redox potential [128]. If we consider their abilities, it could be conceivable to imagine that the use of “natural cocktails,” obtained by mixing different compounds, each of which is able to counteract a specific aspect of HCV infection (entry, replication, and OS generation), could be effective.

In conclusion, we believe that despite the poor results obtained so far by using antioxidant therapies, this antiviral therapeutic strategy should not to be set aside.


This work was supported by grants by MIUR: Fondo per gli Investimenti della Ricerca di Base (FIRB) 2010 (Protocol RBAP10XKNC) titled “Epigenetic and metabolic alterations in the molecular pathogenesis of cancer and the impact of calorie restriction (CR)” and Programma di ricerca di Rilevante Interesse Nazionale (PRIN) 2009 (Protocol 2009YNERCE) titled “Intestinal microflora, steatosis and chronic liver injury.”


  1. “Hepatitis C,” 2013, http://www.who.int/mediacentre/factsheets/fs164/en/. View at: Google Scholar
  2. D. Lavanchy, “The global burden of hepatitis C,” Liver International, vol. 29, no. 1, pp. 74–81, 2009. View at: Publisher Site | Google Scholar
  3. H. R. Rosen and D. R. Gretch, “Hepatitis C virus: current understanding and prospects for future therapies,” Molecular Medicine Today, vol. 5, no. 9, pp. 393–399, 1999. View at: Publisher Site | Google Scholar
  4. R. Bartenschlager, F. Penin, V. Lohmann, and P. André, “Assembly of infectious hepatitis C virus particles,” Trends in Microbiology, vol. 19, no. 2, pp. 95–103, 2011. View at: Publisher Site | Google Scholar
  5. F. Farinati, R. Cardin, M. Bortolami et al., “Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma,” Journal of Viral Hepatitis, vol. 14, no. 12, pp. 821–829, 2007. View at: Publisher Site | Google Scholar
  6. M. Arrese, A. Riquelme, and A. Soza, “Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications,” Annals of Hepatology, vol. 9, no. 1, pp. 112–118, 2010. View at: Google Scholar
  7. L. E. Adinolfi, L. Restivo, R. Zampino, A. Lonardo, and P. Loria, “Metabolic alterations and chronic hepatitis C: treatment strategies,” Expert Opinion on Pharmacotherapy, vol. 12, no. 14, pp. 2215–2234, 2011. View at: Publisher Site | Google Scholar
  8. C.-H. Guo, P.-C. Chen, K.-P. Lin, M.-Y. Shih, and W.-S. Ko, “Trace metal imbalance associated with oxidative stress and inflammatory status in anti-hepatitis C virus antibody positive subjects,” Environmental Toxicology and Pharmacology, vol. 33, no. 2, pp. 288–296, 2012. View at: Publisher Site | Google Scholar
  9. M. Valko, C. J. Rhodes, J. Moncol, M. Izakovic, and M. Mazur, “Free radicals, metals and antioxidants in oxidative stress-induced cancer,” Chemico-Biological Interactions, vol. 160, no. 1, pp. 1–40, 2006. View at: Publisher Site | Google Scholar
  10. M. Rigoulet, E. D. Yoboue, and A. Devin, “Mitochondrial ROS generation and its regulation: mechanisms involved in H2O2 signaling,” Antioxidants and Redox Signaling, vol. 14, no. 3, pp. 459–468, 2011. View at: Publisher Site | Google Scholar
  11. S. W. Ryter, P. K. Hong, A. Hoetzel et al., “Mechanisms of cell death in oxidative stress,” Antioxidants and Redox Signaling, vol. 9, no. 1, pp. 49–89, 2007. View at: Publisher Site | Google Scholar
  12. Y.-M. Go and D. P. Jones, “Redox compartmentalization in eukaryotic cells,” Biochimica et Biophysica Acta, vol. 1780, no. 11, pp. 1273–1290, 2008. View at: Publisher Site | Google Scholar
  13. N. S. R. de Mochel, S. Seronello, S. H. Wang et al., “Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection,” Hepatology, vol. 52, no. 1, pp. 47–59, 2010. View at: Publisher Site | Google Scholar
  14. S. G. Rhee, “H2O2, a necessary evil for cell signaling,” Science, vol. 312, no. 5782, pp. 1882–1883, 2006. View at: Publisher Site | Google Scholar
  15. M. J. Czaja, “Cell signaling in oxidative stress-induced liver injury,” Seminars in Liver Disease, vol. 27, no. 4, pp. 378–389, 2007. View at: Publisher Site | Google Scholar
  16. M. Karbowski and R. J. Youle, “Dynamics of mitochondrial morphology in healthy cells and during apoptosis,” Cell Death and Differentiation, vol. 10, no. 8, pp. 870–880, 2003. View at: Publisher Site | Google Scholar
  17. H. Fujinaga, T. Tsutsumi, H. Yotsuyanagi, K. Moriya, and K. Koike, “Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species,” Oncology, vol. 81, no. 1, pp. 11–17, 2011. View at: Publisher Site | Google Scholar
  18. S. Mahmood, M. Kawanaka, A. Kamei et al., “Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C,” Antioxidants and Redox Signaling, vol. 6, no. 1, pp. 19–24, 2004. View at: Google Scholar
  19. M. Konishi, M. Iwasa, J. Araki et al., “Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane,” Journal of Gastroenterology and Hepatology, vol. 21, no. 12, pp. 1821–1825, 2006. View at: Publisher Site | Google Scholar
  20. M. Arciello, S. Petta, V. Leoni et al., “Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients,” Digestive and Liver Disease, vol. 44, no. 3, pp. 245–250, 2012. View at: Publisher Site | Google Scholar
  21. S. Anticoli, M. Arciello, A. Mancinetti et al., “7-Ketocholesterol and 5,6-secosterol modulate differently the stress-activated mitogen-activated protein kinases (MAPKs) in liver cells,” Journal of Cellular Physiology, vol. 222, no. 3, pp. 586–595, 2010. View at: Publisher Site | Google Scholar
  22. I. C. Gelissen, K.-A. Rye, A. J. Brown, R. T. Dean, and W. Jessup, “Oxysterol efflux from macrophage foam cells: the essential role of acceptor phospholipid,” Journal of Lipid Research, vol. 40, no. 9, pp. 1636–1646, 1999. View at: Google Scholar
  23. M. H. Faulds, C. Zhao, and K. Dahlman-Wright, “Molecular biology and functional genomics of liver X receptors (LXR) in relationship to metabolic diseases,” Current Opinion in Pharmacology, vol. 10, no. 6, pp. 692–697, 2010. View at: Publisher Site | Google Scholar
  24. K. Koike and K. Moriya, “Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH,” Journal of Gastroenterology, vol. 40, no. 4, pp. 329–336, 2005. View at: Publisher Site | Google Scholar
  25. D. Yadav, H. I. Hertan, P. Schweitzer, E. P. Norkus, and C. S. Pitchumoni, “Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C,” American Journal of Gastroenterology, vol. 97, no. 10, pp. 2634–2639, 2002. View at: Publisher Site | Google Scholar
  26. N. Fujita, R. Sugimoto, N. Ma et al., “Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C,” Journal of Viral Hepatitis, vol. 15, no. 7, pp. 498–507, 2008. View at: Publisher Site | Google Scholar
  27. F. Kageyama, Y. Kobayashi, T. Kawasaki, S. Toyokuni, K. Uchida, and H. Nakamura, “Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C,” American Journal of Gastroenterology, vol. 95, no. 4, pp. 1041–1050, 2000. View at: Publisher Site | Google Scholar
  28. D. Thorburn, G. Curry, R. Spooner et al., “The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C,” Gut, vol. 50, no. 2, pp. 248–252, 2002. View at: Publisher Site | Google Scholar
  29. C. Hézode, C. Cazeneuve, O. Coué et al., “Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions,” Journal of Hepatology, vol. 31, no. 6, pp. 979–984, 1999. View at: Publisher Site | Google Scholar
  30. L. Yuan and N. Kaplowitz, “Glutathione in liver diseases and hepatotoxicity,” Molecular Aspects of Medicine, vol. 30, no. 1-2, pp. 29–41, 2009. View at: Publisher Site | Google Scholar
  31. K. Świȩtek and J. Juszczyk, “Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis,” Journal of Viral Hepatitis, vol. 4, no. 2, pp. 139–141, 1997. View at: Google Scholar
  32. G. Barbaro, G. D. Lorenzo, M. Ribersani et al., “Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype,” Journal of Hepatology, vol. 30, no. 5, pp. 774–782, 1999. View at: Publisher Site | Google Scholar
  33. F. Capone, E. Guerriero, A. Sorice et al., “Characterization of metalloproteinases, oxidative status and inflammation levels in the different stages of fibrosis in HCV patients,” Clinical Biochemistry, vol. 45, no. 7-8, pp. 525–529, 2012. View at: Publisher Site | Google Scholar
  34. G. Levent, A. Ali, A. Ahmet et al., “Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy,” Journal of Translational Medicine, vol. 4, article 25, 2006. View at: Publisher Site | Google Scholar
  35. G. Vendemiale, I. Grattagliano, P. Portincasa, G. Serviddio, G. Palasciamo, and E. Altomare, “Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up,” European Journal of Clinical Investigation, vol. 31, no. 1, pp. 54–63, 2001. View at: Publisher Site | Google Scholar
  36. D. L. Diamond, J. M. Jacobs, B. Paeper et al., “Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction,” Hepatology, vol. 46, no. 3, pp. 649–657, 2007. View at: Publisher Site | Google Scholar
  37. Y. Sumida, T. Nakashima, T. Yoh et al., “Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection,” Journal of Hepatology, vol. 33, no. 4, pp. 616–622, 2000. View at: Google Scholar
  38. S. S. Bessa, E. M. Mohamed Ali, S. Abd El-Wahab Ael, and S. A. Nor El-Din, “Heme oxygenase-1 mRNA expression in egyptian patients with chronic liver disease,” Hepatitis Monthly, vol. 12, pp. 278–285, 2012. View at: Google Scholar
  39. O. A. Smirnova, A. V. Ivanov, O. N. Ivanova, V. T. Valuev-Elliston, and S. N. Kochetkov, “Cell defense systems against oxidative stress and endoplasmic reticulum stress: mechanisms of regulation and the effect of hepatitis C virus,” Molecular Biology, vol. 45, no. 1, pp. 110–122, 2011. View at: Publisher Site | Google Scholar
  40. L. M. Aleksunes and J. E. Manautou, “Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease,” Toxicologic Pathology, vol. 35, no. 4, pp. 459–473, 2007. View at: Publisher Site | Google Scholar
  41. D. Burdette, M. Olivarez, and G. Waris, “Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway,” Journal of General Virology, vol. 91, no. 3, pp. 681–690, 2010. View at: Publisher Site | Google Scholar
  42. M. J. Goldenthal and J. Marín-García, “Mitochondrial signaling pathways: a receiver/integrator organelle,” Molecular and Cellular Biochemistry, vol. 262, no. 1-2, pp. 1–16, 2004. View at: Publisher Site | Google Scholar
  43. M. R. Duchen, “Roles of mitochondria in health and disease,” Diabetes, vol. 53, no. 1, pp. S96–S102, 2004. View at: Google Scholar
  44. G. Barbaro, G. Di Lorenzo, A. Asti et al., “Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings,” American Journal of Gastroenterology, vol. 94, no. 8, pp. 2198–2205, 1999. View at: Publisher Site | Google Scholar
  45. H. H. Yen, K. L. Shih, T. T. Lin, W. W. Su, M. S. Soon, and C. S. Liu, “Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C,” World Journal of Gastroenterology, vol. 18, no. 36, pp. 5084–5089, 2012. View at: Google Scholar
  46. A. A. Rowland and G. K. Voeltz, “Endoplasmic reticulum-mitochondria contacts: function of the junction,” Nature Review Molecular Cell Biology, vol. 13, no. 10, pp. 607–625, 2012. View at: Google Scholar
  47. K. W. Kinnally, P. M. Peixoto, S.-Y. Ryu, and L. M. Dejean, “Is mPTP the gatekeeper for necrosis, apoptosis, or both?” Biochimica et Biophysica Acta, vol. 1813, no. 4, pp. 616–622, 2011. View at: Publisher Site | Google Scholar
  48. A. E. Rusiñol, Z. Cui, M. H. Chen, and J. E. Vance, “A unique mitochondria-associated membrane fraction from rat liver has a high capacity for lipid synthesis and contains pre-Golgi secretory proteins including nascent lipoproteins,” Journal of Biological Chemistry, vol. 269, no. 44, pp. 27494–27502, 1994. View at: Google Scholar
  49. C.-I. Popescu and J. Dubuisson, “Role of lipid metabolism in hepatitis C virus assembly and entry,” Biology of the Cell, vol. 102, no. 1, pp. 63–74, 2010. View at: Google Scholar
  50. M. Korenaga, T. Wang, Y. Li et al., “Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production,” Journal of Biological Chemistry, vol. 280, no. 45, pp. 37481–37488, 2005. View at: Publisher Site | Google Scholar
  51. A. Kasprzak, J. Seidel, W. Biczysko, J. Wysocki, R. Spachacz, and M. Zabel, “Intracellular localization of NS3 and C proteins in chronic hepatitis C,” Liver International, vol. 25, no. 4, pp. 896–903, 2005. View at: Publisher Site | Google Scholar
  52. V. C. Chu, S. Bhattacharya, A. Nomoto et al., “Persistent expression of hepatitis C virus non-structural proteins leads to increased autophagy and mitochondrial injury in human hepatoma cells,” PLoS ONE, vol. 6, no. 12, Article ID e28551, 2011. View at: Publisher Site | Google Scholar
  53. B. Schwer, S. Ren, T. Pietschmann et al., “Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif,” Journal of Virology, vol. 78, no. 15, pp. 7958–7968, 2004. View at: Publisher Site | Google Scholar
  54. R. Suzuki, S. Sakamoto, T. Tsutsumi et al., “Molecular determinants for subcellular localization of hepatitis C virus core protein,” Journal of Virology, vol. 79, no. 2, pp. 1271–1281, 2005. View at: Publisher Site | Google Scholar
  55. T. Wang, R. V. Campbell, M. K. Yi, S. M. Lemon, and S. A. Weinman, “Role of hepatitis C virus core protein in viral-induced mitochondrial dysfunction,” Journal of Viral Hepatitis, vol. 17, no. 11, pp. 784–793, 2010. View at: Google Scholar
  56. B. Wölk, D. Sansonno, H.-G. Kräusslich et al., “Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines,” Journal of Virology, vol. 74, no. 5, pp. 2293–2304, 2000. View at: Publisher Site | Google Scholar
  57. S. Griffin, D. Clarke, C. McCormick, D. Rowlands, and M. Harris, “Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes,” Journal of Virology, vol. 79, no. 24, pp. 15525–15536, 2005. View at: Publisher Site | Google Scholar
  58. Y. Nomura-Takigawa, M. Nagano-Fujii, L. Deng et al., “Non-structural protein 4A of Hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis,” Journal of General Virology, vol. 87, no. 7, pp. 1935–1945, 2006. View at: Publisher Site | Google Scholar
  59. S. M. Horner, H. M. Liu, H. S. Park, J. Briley, and M. Gale Jr., “Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 35, pp. 14590–14595, 2011. View at: Publisher Site | Google Scholar
  60. H. F. Galley, “Bench-to-bedside review: targeting antioxidants to mitochondria in sepsis,” Critical Care, vol. 14, no. 4, article 230, 2010. View at: Publisher Site | Google Scholar
  61. M. P. Murphy, “How mitochondria produce reactive oxygen species,” Biochemical Journal, vol. 417, no. 1, pp. 1–13, 2009. View at: Publisher Site | Google Scholar
  62. C. Piccoli, R. Scrima, G. Quarato et al., “Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress,” Hepatology, vol. 46, no. 1, pp. 58–65, 2007. View at: Publisher Site | Google Scholar
  63. M. Ando, M. Korenaga, K. Hino et al., “Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication,” Liver International, vol. 28, no. 8, pp. 1158–1166, 2008. View at: Publisher Site | Google Scholar
  64. K. Moriya, K. Nakagawa, T. Santa et al., “Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis,” Cancer Research, vol. 61, no. 11, pp. 4365–4370, 2001. View at: Google Scholar
  65. M. Y. Abdalla, I. M. Ahmad, D. R. Spitz, W. N. Schmidt, and B. E. Britigan, “Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses,” Journal of Medical Virology, vol. 76, no. 4, pp. 489–497, 2005. View at: Publisher Site | Google Scholar
  66. H. A. Sayed, A. El Ayyat, H. El Dusoki et al., “A cross sectional study of hepatitis B, C, some trace elements, heavy metals, aflatoxin B1 and schistosomiasis in a rural population, Egypt,” The Journal of the Egyptian Public Health Association, vol. 80, no. 3-4, pp. 355–388, 2005. View at: Google Scholar
  67. J. C. King, “Determinants of maternal zinc status during pregnancy,” American Journal of Clinical Nutrition, vol. 71, no. 5, 2000. View at: Google Scholar
  68. P. I. Oteiza, “Zinc and the modulation of redox homeostasis,” Free Radical Biology and Medicine, vol. 53, no. 9, pp. 1748–1759, 2012. View at: Google Scholar
  69. G. A. Rutter, “Think zinc: new roles for zinc in the control of insulin secretion,” Islets, vol. 2, no. 1, pp. 49–50, 2010. View at: Google Scholar
  70. K. Jomova and M. Valko, “Advances in metal-induced oxidative stress and human disease,” Toxicology, vol. 283, no. 2-3, pp. 65–87, 2011. View at: Publisher Site | Google Scholar
  71. D. Moradpour and F. Penin, “Hepatitis C virus proteins: from structure to function,” Current Topics in Microbiology and Immunology, vol. 369, pp. 113–142, 2013. View at: Google Scholar
  72. T. Himoto, N. Hosomi, S. Nakai et al., “Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease,” Scandinavian Journal of Gastroenterology, vol. 42, no. 9, pp. 1078–1087, 2007. View at: Publisher Site | Google Scholar
  73. Y. Murakami, T. Koyabu, A. Kawashima et al., “Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon α-2b and ribavirin,” Journal of Nutritional Science and Vitaminology, vol. 53, no. 3, pp. 213–218, 2007. View at: Publisher Site | Google Scholar
  74. A. S. Prasad, “Zinc: role in immunity, oxidative stress and chronic inflammation,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 12, no. 6, pp. 646–652, 2009. View at: Publisher Site | Google Scholar
  75. T. Kanda, O. Yokosuka, K. Nagao, and H. Saisho, “State of hepatitis C viral replication enhances activation of NF-kB- and AP-1-signaling induced by hepatitis B virus X,” Cancer Letters, vol. 234, no. 2, pp. 143–148, 2006. View at: Publisher Site | Google Scholar
  76. S. Matsuoka, H. Matsumura, H. Nakamura et al., “Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis,” Journal of Clinical Biochemistry and Nutrition, vol. 45, no. 3, pp. 292–303, 2009. View at: Publisher Site | Google Scholar
  77. H. Matsumura, K. Nirei, H. Nakamura et al., “Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C,” Journal of Clinical Biochemistry and Nutrition, vol. 51, no. 3, pp. 178–184, 2012. View at: Google Scholar
  78. K. Yuasa, A. Naganuma, K. Sato et al., “Zinc is a negative regulator of hepatitis C virus RNA replication,” Liver International, vol. 26, no. 9, pp. 1111–1118, 2006. View at: Publisher Site | Google Scholar
  79. G. J. Cooper, “Selective divalent copper chelation for the treatment of diabetes mellitus,” Current Medicinal Chemistry, vol. 19, no. 17, pp. 2828–2860, 2012. View at: Google Scholar
  80. B. Li, Y. Tan, W. Sun, Y. Fu, L. Miao, and L. Cai, “The role of zinc in the prevention of diabetic cardiomyopathy and nephropathy,” Toxicology Mechanisms and Methods, vol. 23, no. 1, pp. 27–33, 2013. View at: Google Scholar
  81. C. H. Guo, P. C. Chen, and W. S. Ko, “Status of essential trace minerals and oxidative stress in viral hepatitis C patients with nonalcoholic fatty liver disease,” Internaional Journal of Medical Science, vol. 10, no. 6, pp. 730–737, 2013. View at: Google Scholar
  82. W.-S. Ko, C.-H. Guo, M.-S. Yeh et al., “Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C,” World Journal of Gastroenterology, vol. 11, no. 30, pp. 4697–4702, 2005. View at: Google Scholar
  83. E. A. Roberts and M. L. Schilsky, “Diagnosis and treatment of Wilson disease: an update,” Hepatology, vol. 47, no. 6, pp. 2089–2111, 2008. View at: Publisher Site | Google Scholar
  84. M. C. Linder, “The relationship of copper to DNA damage and damage prevention in humans,” Mutation Research, vol. 733, no. 1-2, pp. 83–91, 2012. View at: Publisher Site | Google Scholar
  85. M. D. Mattie and J. H. Freedman, “Copper-inducible transcription: regulation by metal- and oxidative stress-responsive pathways,” American Journal of Physiology, vol. 286, no. 2, pp. C293–C301, 2004. View at: Google Scholar
  86. R. P. Patel and V. M. Darley-Usmar, “Molecular mechanisms of the copper dependent oxidation of low-density lipoprotein,” Free Radical Research, vol. 30, no. 1, pp. 1–9, 1999. View at: Google Scholar
  87. M. Nakhjavani, A. Mashayekh, O. Khalilzadeh et al., “Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C,” Clinics and Research in Hepatology and Gastroenterology, vol. 35, no. 2, pp. 111–116, 2011. View at: Publisher Site | Google Scholar
  88. T. Von Hahn, B. D. Lindenbach, A. Boullier et al., “Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells,” Hepatology, vol. 43, no. 5, pp. 932–942, 2006. View at: Publisher Site | Google Scholar
  89. S. Westhaus, D. Bankwitz, S. Ernst et al., “Characterization of the inhibition of hepatitis C virus entry by In vitro-generated and patient-derived oxidized low-density lipoprotein,” Hepatology, vol. 57, no. 5, pp. 1716–1724, 2013. View at: Google Scholar
  90. R. J. Jones, S. J. Lewis, J. M. Smith, and J. Neuberger, “Undetectable serum caeruloplasmin in a woman with chronic hepatitis C infection,” Journal of Hepatology, vol. 32, no. 4, pp. 703–704, 2000. View at: Publisher Site | Google Scholar
  91. C. Fillebeen, M. Muckenthaler, B. Andriopoulos et al., “Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells,” Journal of Hepatology, vol. 47, no. 1, pp. 12–22, 2007. View at: Publisher Site | Google Scholar
  92. F. Duygu, S. T. Koruk, H. Karsen, N. Aksoy, A. Taskin, and M. Hamidanoglu, “Prolidase and oxidative stress in chronic hepatitis C,” Journal of Clinical Laboratory Analysis, vol. 26, no. 4, pp. 232–237, 2012. View at: Google Scholar
  93. G. J. Anderson and F. Wang, “Essential but toxic: controlling the flux of iron in the body,” Clinical and Experimental Pharmacology and Physiology, vol. 39, no. 8, pp. 719–724, 2012. View at: Google Scholar
  94. D. N. Martin and S. L. Uprichard, “Identification of transferrin receptor 1 as a hepatitis C virus entry factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 26, pp. 10777–10782, 2013. View at: Google Scholar
  95. R. J. Fontana, J. Israel, P. LeClair et al., “Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial,” Hepatology, vol. 31, no. 3, pp. 730–736, 2000. View at: Google Scholar
  96. H. Hofer, C. Österreicher, W. Jessner et al., “Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C,” Journal of Hepatology, vol. 40, no. 6, pp. 1018–1022, 2004. View at: Publisher Site | Google Scholar
  97. M. Yano, H. Hayashi, K. Yoshioka et al., “A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomised, controlled trial in Japan,” Journal of Gastroenterology, vol. 39, no. 6, pp. 570–574, 2004. View at: Google Scholar
  98. N. Fujita, R. Sugimoto, N. Urawa et al., “Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C,” Journal of Gastroenterology and Hepatology, vol. 22, no. 11, pp. 1886–1893, 2007. View at: Publisher Site | Google Scholar
  99. J. Lopez-Prieto, E. Gonzalez-Reimers, M. R. Aleman-Valls et al., “Iron and proinflammatory cytokines in chronic hepatitis C virus infection,” Biological Trace Element Research, vol. 155, no. 1, pp. 5–10, 2013. View at: Google Scholar
  100. D. Trinder, O. T. Ayonrinde, and J. K. Olynyk, “HCV, iron, and oxidative stress: the new choreography of hepcidin,” Gastroenterology, vol. 134, no. 1, pp. 348–351, 2008. View at: Publisher Site | Google Scholar
  101. S. Nishina, K. Hino, M. Korenaga et al., “Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription,” Gastroenterology, vol. 134, no. 1, pp. 226–238, 2008. View at: Publisher Site | Google Scholar
  102. H. Liu, T. L. Trinh, H. Dong, R. Keith, D. Nelson, and C. Liu, “Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus,” PLoS ONE, vol. 7, no. 10, Article ID e46631, 2012. View at: Google Scholar
  103. A. V. Ivanov, B. Bartosch, O. A. Smirnova, M. G. Isaguliants, and S. N. Kochetkov, “HCV and oxidative stress in the liver,” Viruses, vol. 5, no. 2, pp. 439–469, 2013. View at: Google Scholar
  104. T. Furutani, K. Hino, M. Okuda et al., “Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein,” Gastroenterology, vol. 130, no. 7, pp. 2087–2098, 2006. View at: Publisher Site | Google Scholar
  105. M. L.-H. Huang, D. J. R. Lane, and D. R. Richardson, “Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease,” Antioxidants and Redox Signaling, vol. 15, no. 12, pp. 3003–3019, 2011. View at: Publisher Site | Google Scholar
  106. S. C. Leary, “Redox regulation of SCO protein function: controlling copper at a mitochondrial crossroad,” Antioxidants and Redox Signaling, vol. 13, no. 9, pp. 1403–1416, 2010. View at: Publisher Site | Google Scholar
  107. J. M. Pawlotsky, “Treatment of chronic hepatitis C: current and future,” Current Topics in Microbiology and Immunology, vol. 369, pp. 321–342, 2013. View at: Google Scholar
  108. L. C. Casey and W. M. Lee, “Hepatitis C virus therapy update 2013,” Current Opinion in Gastroenterology, vol. 29, no. 3, pp. 243–249, 2013. View at: Google Scholar
  109. S. Seronello, J. Montanez, K. Presleigh, M. Barlow, S. B. Park, and J. Choi, “Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals,” PLoS ONE, vol. 6, no. 11, Article ID e27436, 2011. View at: Publisher Site | Google Scholar
  110. R. A. J. Smith, C. M. Porteous, A. M. Gane, and M. P. Murphy, “Delivery of bioactive molecules to mitochondria in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5407–5412, 2003. View at: Publisher Site | Google Scholar
  111. M. P. Murphy and R. A. J. Smith, “Targeting antioxidants to mitochondria by conjugation to lipophilic cations,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 629–656, 2007. View at: Publisher Site | Google Scholar
  112. M. L. Jauslin, T. Meier, R. A. J. Smith, and M. P. Murphy, “Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants,” FASEB Journal, vol. 17, pp. 1972–1974, 2003. View at: Google Scholar
  113. E. J. Gane, F. Weilert, D. W. Orr et al., “The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients,” Liver International, vol. 30, no. 7, pp. 1019–1026, 2010. View at: Publisher Site | Google Scholar
  114. P. A. Gallay, “Cyclophilin Inhibitors,” Clinics in Liver Disease, vol. 13, no. 3, pp. 403–417, 2009. View at: Publisher Site | Google Scholar
  115. J. Paeshuyse, A. Kaul, E. De Clercq et al., “The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro,” Hepatology, vol. 43, no. 4, pp. 761–770, 2006. View at: Publisher Site | Google Scholar
  116. R. Crabbé, G. Vuagniaux, J.-M. Dumont, V. Nicolas-Métral, J. Marfurt, and L. Novaroli, “An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C,” Expert Opinion on Investigational Drugs, vol. 18, no. 2, pp. 211–220, 2009. View at: Publisher Site | Google Scholar
  117. L. Coelmont, S. Kaptein, J. Paeshuyse et al., “Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 3, pp. 967–976, 2009. View at: Publisher Site | Google Scholar
  118. P. A. Gallay and K. Lin, “Profile of alisporivir and its potential in the treatment of hepatitis C,” Journal of Drug Design, Development and Therapy, vol. 7, pp. 105–115, 2013. View at: Google Scholar
  119. G. Quarato, A. D'Aprile, B. Gavillet et al., “The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction,” Hepatology, vol. 55, no. 5, pp. 1333–1343, 2012. View at: Publisher Site | Google Scholar
  120. K. Grüngreiff and D. Reinhold, “Zinc: a complementary factor in the treatment of chronic hepatitis C? (Review),” Molecular Medicine Reports, vol. 3, no. 3, pp. 371–375, 2010. View at: Publisher Site | Google Scholar
  121. S. Fargion, A. Ludovica Fracanzani, M. Sampietro et al., “Liver iron influences the response to interferon alpha therapy in chronic hepatitis C,” European Journal of Gastroenterology and Hepatology, vol. 9, no. 5, pp. 497–503, 1997. View at: Google Scholar
  122. N. Calland, J. Dubuisson, Y. Rouille, and K. Seron, “Hepatitis C virus and natural compounds: a new antiviral approach?” Viruses, vol. 4, no. 10, pp. 2197–2217, 2012. View at: Google Scholar
  123. M. Zatloukalová, V. Křen, R. Gažák et al., “Electrochemical investigation of flavonolignans and study of their interactions with DNA in the presence of Cu(II),” Bioelectrochemistry, vol. 82, no. 2, pp. 117–124, 2011. View at: Publisher Site | Google Scholar
  124. L. Rossi, S. Mazzitelli, M. Arciello, C. R. Capo, and G. Rotilio, “Benefits from dietary polyphenols for brain aging and Alzheimer's disease,” Neurochemical Research, vol. 33, no. 12, pp. 2390–2400, 2008. View at: Publisher Site | Google Scholar
  125. D. S. Han, B. Hahm, H.-M. Rho, and S. K. Jang, “Identification of the protease domain in NS3 of hepatitis C virus,” Journal of General Virology, vol. 76, no. 4, pp. 985–993, 1995. View at: Google Scholar
  126. G. Bartolomei, R. E. Cevik, and A. Marcello, “Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes,” Journal of General Virology, vol. 92, no. 9, pp. 2072–2081, 2011. View at: Publisher Site | Google Scholar
  127. J. Choi, “Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations,” Free Radical Biology and Medicine, vol. 52, no. 7, pp. 1135–1150, 2012. View at: Publisher Site | Google Scholar
  128. N. R. Perron, C. R. García, J. R. Pinzón, M. N. Chaur, and J. L. Brumaghim, “Antioxidant and prooxidant effects of polyphenol compounds on copper-mediated DNA damage,” Journal of Inorganic Biochemistry, vol. 105, no. 5, pp. 745–753, 2011. View at: Publisher Site | Google Scholar

Copyright © 2013 Mario Arciello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1718 Views | 832 Downloads | 18 Citations
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.